Clinical Research Directory

DISEASE CHARACTERISTICS: * Histologically confirmed non-small cell lung cancer * Locally advanced disease * No metastatic disease * Unable to undergo surgery after concurrent chemoradiotherapy * Must have 1-3 tumor target masses \< 5 cm in greatest diameter and separated by ≥ 2 cm after concurrent chemoradiotherapy PATIENT CHARACTERISTICS: * WHO performance status 0-2 * Platelet count \> 100,000/mm³ * Hemoglobin \> 9 g/dL * Neutrophil \> 1.0 x 10\^9/L * FEV\_1 \> 30% of vital capacity * Vital capacity \> 25% of predicted value * DLCO \> 25% of predicted value * LVEF ≥ 35% * PT \> 80 * aPTT \> 35 sec * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after completion of study treatment * Not under guardianship * No dyspnea related to NYHA class III-IV heart failure * No indirect signs of pulmonary arterial hypertension (pulmonary arterial systolic BP \> 45 mm Hg) * No pulmonary acceleration time \< 100 ms * No contraindication to fiducial insertion * No geographical, social, or psychological conditions that would interfere with medical follow-up PRIOR CONCURRENT THERAPY: * Docetaxel and platinum-based drugs with concurrent irradiation allowed * No prior surgery or surgery after the first phase of treatment with concurrent chemoradiotherapy * No prior irradiation to lung * No concurrent participation in another study trial